SafelyYou, Andes, Rune Labs
Egyptian Healthtech Sotech Raises USD 1 Mn pre-Seed Round
Sotech, an Egypt-based healthtech, and IoT solutions startup has raised USD 1 Mn in a pre-Seed funding round led by Innlife Investments and Al Raya Kuwaiti, a key corporate investor.
The startup plans to utilize its newly acquired funds to scale to 500 venues and expand its market in Saudi Arabia. It also will use it to avoid, track, and contain infectious diseases.
Sotech specializes in smart IoT, trackable out-of-home advertising, and data collection to assist clinics in better understand their visitors’ volume, flow, and demographics. The data is also linked to an advertising dashboard, which allows marketers to track the performance of their in-clinic ads.
Egyptian Healthtech Sotech Raises USD 1 Mn pre-Seed Round
Sotech, an Egypt-based healthtech, and IoT solutions startup has raised USD 1 Mn
Andes Raises USD$15M in Series A Funding
Andes, an Emeryville, CA-based agriculture and biotechnology company, raised USD15m in Series A funding.
The round was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Cavallo Ventures, with participation from new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini and existing investors KdT Ventures and Endurance.
The company intends to use the funds to scale its self-sustaining, nitrogen-fixing seeds across the U.S. market, expand into South America, and to advance further research and development into its complementary nature-based permanent carbon capture technology.
Led by Gonzalo Fuenzalida, CEO, Andes develops biological solutions enabling positive action for fighting climate change. Its first generation of solutions focus on the agricultural industry. Through its novel microbial seed treatment technology called Microprime, the company reduces the need for synthetic fertilizers and enables the seed to draw down nitrogen from the air. Andes is also developing microbes for plant roots and can create nature-based permanent carbon capture solutions to sequester and store CO2 from the atmosphere into the soil.
Andes Raises USD$15M in Series A Funding
Andes, an Emeryville, CA-based agriculture and biotechnology company, raised USD15m in Series A funding
SafelyYou Closes $19.5M Series A Funding Round
SafelyYou, a San Francisco, CA-based provider of artificial intelligence-enabled fall detection and prevention for dementia care, closed a $19.5m Series A financing round.
The round was led by Eclipse Ventures with participation from Founders Fund, as well as existing investors DCVC and Foundation Capital. TSQ Advisors, Pathbreaker Ventures, The House Fund, Swift Ventures, Pacific Health Ventures, Anorak Ventures, and 7Percent Ventures.
The company intends to use the funds to scale up its assisted living and skilled nursing business.
Originating in 2015 as the doctoral research of CEO George Netscher at the UC Berkeley Artificial Intelligence Research Lab, SafelyYou utilizes artificial intelligence to empower care staff to implement fall prevention. Specifically designed for memory care, or care for residents with Alzheimer’s disease and related dementias, the company’s subsequent fall video review provides support for unwitnessed falls through ER decision making and root cause analysis to support fall prevention. Privacy and liability are protected through cameras that only activate when a fall is detected.
SafelyYou Closes $19.5M Series A Funding Round
SafelyYou, a San Francisco, CA-based provider of artificial intelligence-enabled fall detection and prevention for dementia care, closed a $19.5m Series A financing round
Anjarium Biosciences Raises $61M in Series A Financing
Anjarium Biosciences AG, a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies, closed a CHF55.5M ($61M) Series A financing.
The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). In conjunction with Anjarium’s Series A financing, Dr. Bali Muralidhar of Abingworth, Dr. Bram Vanparys of Gimv and Dr. Dina Chaya of Omega Funds will join the company’s Board of Directors.
The company intends to use the funds to expand its team, advance its platform and progress several therapeutic pipeline programs towards clinical development.
Led by Joël de Beer, Founder and CSO, Anjarium Biosciences leverages a platform at the interface of genetic medicine, synthetic biology and nanoparticle engineering to to rationally design and produce tissue-targeted gene therapies, optimized to improve patient outcomes in a range of serious genetic diseases.
Anjarium Biosciences Raises $61M in Series A Financing - FinSMEs
Anjarium Biosciences AG, a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies, closed a CHF55.5M ($61M) Series A financing
Amolyt Pharma Raises $80M in Series B Financing
Amolyt Pharma, a Lyon, France and Cambridge, Mass.-based company specialized in developing therapeutic peptides for rare endocrine and related diseases, closed an $80m Series B equity financing round.
The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
Led by Thierry Abribat, Ph.D., founder, and chief executive officer, Amolyt Pharma is a clinical stage biotechnology company advancing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma Raises $80M in Series B Financing
Amolyt Pharma, a Lyon, France and Cambridge, Mass.-based company specialized in developing therapeutic peptides for rare endocrine and related diseases, closed an $80m Series B equity financing round
accuRx Raises £27.5M in Series B Funding
accuRx, a London, UK-based healthcare platform, raised £27.5M in Series B funding.
The round was led by Lakestar with participation from British Patient Capital, Latitude VS (sister fund to London-based seed investor LocalGlobe), Atomico, Trusted Insight and Encore Capital.
The newly raised funds will facilitate the growth of the team, enhancing its offering to GP practices and building products that will enable expansion into secondary care.
Led by Jacob Haddad, CEO, and Laurence Bargery, CTO, accuRx offers a collaborative communications platform that brings patients and their healthcare teams together. It allows existing health and care systems to deliver technology-enabled care, beginning with the National Health Service (NHS) in the UK. The software is currently used by 98% of GP practices in England and a growing number of hospitals and community trusts to communicate with their patients and one another.
accuRx Raises £27.5M in Series B Funding - FinSMEs
accuRx, a London, UK-based healthcare platform, raised £27.5M in Series B funding. The round was led by Lakestar
SmartLabs Raises $250M in Series B Funding
SmartLabs, a Boston WA-based Laboratory-as-a-Service (LaaS) company, raised $250M in Series B funding.
The round was led by ArrowMark Partners with participation from Winslow Capital Management and Onex Falcon, Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
The company intends to use the funds to accelerate growth, with a plan to scale operations to 2 million square feet within five years.
Led by Amrit Chaudhuri, CEO, SmartLabs designs, builds, and operates integrated, enterprise-grade research environments, including multifunctional research and development labs, vivariums, process development, pilot-scale manufacturing, and cGMP suites for companies of all sizes.
SmartLabs Raises $250M in Series B Funding - FinSMEs
SmartLabs, a Boston WA-based Laboratory-as-a-Service (LaaS) company, raised $250M in Series B funding
Caresyntax Raises Additional $30M; Brings Series C To $130M
Caresyntax, a Boston WA-based digital surgery platform, raised an additional $30M which brought total Series C to $130M.
This round was led by PFM Health Sciences, with participation from funds and accounts managed by BlackRock, as well as ProAssurance, Harmonix, and existing investors such as the Relyens Group and IPF Partners. The first stage announced in April 2021 also included investments from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, and Surgical.AI.
The company intends to use the funds to continue developing its platform as well as advance new data solutions that support value-based care providers.
Founded by entrepreneurs Dennis Kogan and Björn von Siemens, Caresyntax provides a digital surgery platform that delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR.
https://www.finsmes.com/2021/09/caresyntax-raises-additional-30m-brings-series-c-to-130m.html
Bantam Pharmaceutical Closes $25M Seed Funding
Bantam Pharmaceutical, a Research Triangle Park, N.C.-based drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, closed a $25m seed funding.
The round was co-led by current investors including Lionel Goldfrank, who also is a board member.
The company intends to use the funds to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials.
Led by Michael Stocum, President and Chief Executive Officer, Bantam Pharmaceutical is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company’s current clinical development strategy is focused on B-cell hematological malignancies with expansion into additional patient cohorts based on responses in biomarker-selected patient populations.
Bantam Pharmaceutical Closes $25M Seed Funding - FinSMEs
Bantam Pharmaceutical, a Research Triangle Park, N.C.-based drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, closed a $25m seed funding
RareCyte Secures $24M Financing
RareCyte, Inc., a Seattle, WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing.
Arboretum Ventures led the financing joined by other new investors F-Prime Capital, Logos Capital, and Agilent Technologies. Existing investors participating in the financing included HealthQuest Capital, 5AM Ventures, and Company founder Ron Seubert. Jan Garfinkle, Arboretum Managing Partner, joined the RareCyte Board of Directors along with Robert Weisskoff, Ph.D., Partner at F-Prime Capital.
The company intends to use the funds to drive the commercialization and applications for its new Orion spatial biology platform and further global expansion for its portfolio of instruments and consumables.
Led by Joe Victor, President and CEO, RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The company has deep experience in developing advanced precision life science systems used in labs worldwide.
RareCyte Secures $24M Financing - FinSMEs
RareCyte, Inc., a Seattle, WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing
Rune Labs Raises $22.8M in Series A Financing
Rune Labs, a San Francisco, CA-based brain data company enabling the advancement and delivery of precision neuroscience therapeutics, raised $22.8m in Series A financing.
The round was led by Eclipse Ventures with participation from current investors including DigiTx Partners and Moment Ventures. In conjunction with the funding, Justin Butler, Partner at Eclipse, will join the Rune Labs Board of Directors.
The financing will enable the company to expand the number of patients, clinicians, and researchers using its platform.
Led by Brian Pepin, founder and CEO, Rune Labs is empowering the development of precision medicines for Parkinson’s disease, multiple sclerosis, depression and other neurodegenerative disorders by using its software platform to make brain data useful at scale. Rune’s precision brain data software platform integrates electrophysiology, brain imaging, and device data together with wearable data and clinical labels. The combination will provide researchers, drug developers, and clinicians with the tools to guide treatment, uncover hidden disease phenotypes, and design targeted therapies.
